{
  "id": 2383130,
  "title": "Blood-camouflaged nanoparticles defeat drug-resistant breast tumors in mouse model",
  "url": "https://urgent.news/2026/08/21/blood-camouflaged-nanoparticles-defeat-drug-resistant-breast-tumors",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-21T13:40:03.000Z",
  "source": {
    "name": "Phys.org",
    "slug": "phys-org",
    "url": "https://phys.org/news/2026-08-blood-camouflaged-nanoparticles-defeat-drug.html"
  },
  "original_language": "en",
  "account": "Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of all breast cancer cases. Unlike other breast cancers, TNBC lacks targetable receptors, making chemotherapy the primary treatment option. Immunotherapy has limited effectiveness in TNBC patients due to the high presence of regulatory T cells (Tregs) that suppress the immune system. Scientists at Tohoku University have created a multifunctional nanoplatform called B-LM-DMX-αCD25 that tackles three key challenges in TNBC immunotherapy. The platform uses gallium-based liquid metal nanoparticles coated with whole-blood components, allowing them to evade immune clearance and accumulate in tumors. Once at the tumor site, the nanoparticles eliminate intratumoral Tregs, heat the tumor to 58°C using near-infrared laser irradiation, and release a STING agonist (DMX) to activate innate immunity. In preclinical studies, the B-LM-DMX-αCD25 platform achieved complete tumor regression, reduced lung metastases by 90%, and extended median survival beyond 70 days in drug-resistant TNBC mouse models. The researchers aim to adapt this platform to other solid tumors with immune-suppressive environments, such as pancreatic and ovarian cancers, and are preparing GLP-compliant toxicology studies for potential clinical translation.",
  "summary": "Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15% to 20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}